Production of adenovirus vectors with reduced levels of replication competent adenovirus contamination
AssigneeAdVec, Inc.
InventorFrank Graham
Life of this patent
Estimating the term…
Loading patent…
AssigneeAdVec, Inc.
InventorFrank Graham
Estimating the term…
Methods, cells and recombinant adenoviral vectors are disclosed that permit the production of recombinant adenoviral vector stocks with reduced levels of contamination by replication competent adenoviruses (RCA). In certain embodiments are disclosed early region 1 (E1) deficient recombinant adenoviral vectors and complementing E1 positive host cells whose sequences are designed to avoid formation of RCA by homologous recombination between sequences in the vector and E1 sequences in the cells. One aspect of the invention involves the inversion of the packaging signal in a recombinant adenoviral vector relative to an adjacent or nearby inverted terminal repeat (ITR). Methods include use of site-specific intregrase family recombinases such as Cre or FLP and recombinase recognition sites such as lox sites or frt sites.
A recombinant adenoviral nucleic acid sequence comprising:
A recombinant adenoviral nucleic acid sequence comprising:
A recombinant adenoviral vector comprising an inverted packaging signal and further comprising an insertion of foreign DNA comprising an expression cassette comprising an introduced DNA sequence, a promoter operatively linked to the introduced DNA sequence, and a termination sequence.
A shuttle plasmid comprising an origin of replication, a selectable marker, and an adenoviral DNA sequence comprising an inverted terminal repeat (ITR), a packaging signal in an inverted orientation with respect to the ITR, and a cloning site.
A system for propagation of recombinant adenoviral vector comprising
A method for producing a recombinant adenoviral vector comprising a gene of interest, said method not producing a vector having a functional E1 region, said method comprising:
Dependencies are inferred from the claim text.